logo conference-reports

Conference Reports

Educational service by logo MSD Oncology

ASCO-GI 2019—Dabrafenib/trametinib yields high response in BRAF+ BTC

Phase 2 ROAR data show high response rate in BRAF V600E-mutated disease.